36 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Negrin, Hematologist in Stanford, CA?
Dr. Robert Negrin, MD is a Hematologist, who primarily practices in Stanford, CA with 1 additional practice location. He has been practicing for over 36 years and is board certified. Dr. Negrin completed his residency at Stanford University School of Medicine. Dr. Negrin is fluent in English and Spanish, and is currently seeing new patients. Dr. Negrin’s practice accepts Kaiser Permanente, Medicaid, Medicare, Aetna, Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Negrin’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Negrin?
Dr. Robert Negrin, MD is a highly-rated, board-certified Hematologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Negrin empowers patients to confidently navigate their health journey, specializing in Bone Marrow Transplant, Hematologic Malignancies, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Negrin is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Negrin go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine,Stanford, Ca, United States
Residency: Stanford University School of Medicine
Is Dr. Negrin board certified as a Hematologist?
Yes, Dr. Robert Negrin, MD is board certified by the American Board of Internal Medicine , American Board of Internal Medicine since 1992, American Board of Internal Medicine since 1987
What languages does Dr. Negrin speak?
Dr. Negrin and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does a Hematologist like Dr. Negrin typically treat?
As a Hematologist, Dr. Negrin diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Negrin. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Acute Myeloid Leukemia in Remission
- Acute Myeloid Leukemia
- AML Leukemia in Remission
- Acute Myeloblastic Leukemia in Remission
- Acute Myelogenous Leukemia in Remission
ICD-10 Codes:
- C9201: Acute myeloblastic leukemia, in remission
Also known as:
- Multiple Myeloma
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)
- Active multiple myeloma
- Untreated multiple myeloma
- Plasma cell myeloma
ICD-10 Codes:
- C9000: Multiple myeloma not having achieved remission
Also known as:
- Myelodysplastic Syndrome
- Myelodysplastic Syndromes
- Myelodysplastic Syndromes Treatment (PDQ®)
- MDS
- Preleukemia
- Bone marrow failure disorder
ICD-10 Codes:
- D469: Myelodysplastic syndrome, unspecified
Also known as:
- Bone Marrow Transplant
- Bone Marrow Transplantation
- Stem Cell Transplant
- Hematopoietic Stem Cell Transplant
- Marrow Transplant
ICD-10 Codes:
- Z9481: Bone marrow transplant status
What procedures does a Hematologist like Dr. Negrin typically perform?
As a Hematologist, Dr. Negrin performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Negrin. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Bone Marrow Biopsy and Aspiration
- Biopsy
- Bone Marrow Tests
- Bone Marrow Exam
- Bone Marrow Sample Collection
- Diagnostic Bone Marrow Procedure
CPT Codes:
- 38222: Diagnostic bone marrow; biopsy(ies) and aspiration(s)
Also known as:
- Stem Cell Freezing and Storage
- Hematopoietic Stem Cell Cryopreservation
- Blood Stem Cell Storage
- Bone Marrow Stem Cell Banking
CPT Codes:
- 38207: Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage
Also known as:
- Collecting Patient's Own Blood Stem Cells for Transplant
- Autologous Stem Cell Harvest
- Blood Stem Cell Collection
- Hematopoietic Stem Cell Apheresis
CPT Codes:
- 38206: Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
Also known as:
- Thawing Frozen Stem Cells for Transplant
- Hematopoietic stem cell thawing
- Bone marrow cell preparation
- Frozen cell thaw
- Stem cell transplant prep
CPT Codes:
- 38208: Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor
Also known as:
- Autologous Stem Cell Transplant
- Bone Marrow Transplantation
- Autologous Bone Marrow Transplant
- HPC Transplant
- Self Stem Cell Transplant
CPT Codes:
- 38241: Hematopoietic progenitor cell (HPC); autologous transplantation
Also known as:
- Blood Transfusion
- Blood Transfusion and Donation
- Blood product transfusion
- Red blood cell transfusion
- Plasma transfusion
CPT Codes:
- 36430: Transfusion, blood or blood components
Also known as:
- Removal of Tunneled Central Venous Catheter
- Central Line Removal
- Tunneled Catheter Extraction
- Venous Access Device Removal
CPT Codes:
- 36589: Removal of tunneled central venous catheter, without subcutaneous port or pump
Does Dr. Negrin accept my insurance?
Dr. Negrin accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Negrin accept in Stanford, CA?
Dr. Negrin in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
CVS Health (formerly Aetna)
Imperial Health Holdings
Kaiser Permanente
Medicaid
Medicare
State of California
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Negrin's office located?
Recognitions
Publications
Role of lymphocyte activation gene-3
, 2014
Regulatory T cells and tural killer T cells for modulation of GVHD following allogeneic
, 2013
A distinct evolution of the T
, 2013
Mapping immune processes in intact tissues at cellular resolution.
, 2012
Mapping immune processes in intact tissues at cellular resolution
, 2012
Co-transplantation of pure blood stem cells with antigen
, 2012
Low doses of tural killer T cells provide protection from acute graft-versus
, 2011
Long-term outcomes in patients with high
, 2011
tural and Expanded CD4(+) CD25(+) Regulatory T Cells in Bone Marrow Transplantation
, 2011
CD11B+CD11C+DENDRITIC CELLS INTERACT WITH ALLOREACTIVE T CELLS IN THE INTESTIL MUCOSA IN ACUTE
, 2010
Biology and clinical effects of tural killer cells in allogeneic transplantation
, 2010
Immunoglobulin G Fc Receptor Fc gamma RIIIa 158 V
, 2010
Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation
, 2009
tural Killer Cells in Allogeneic Transplantation: Effect on Engraftment, Graft- versus-Tumor
, 2009
Regulation of different inflammatory diseases by impacting the mevalote pathway
, 2009
Glycogen synthase kise 3 beta missplicing contributes to leukemia stem cell generation
, 2009
Follicular lymphoma B cells induce the conversion of conventiol CD4
, 2009
Impact of mammalian target of rapamycin inhibition on lymphoid homing
, 2008
Plasmacytoid dendritic cells take up opsonized antigen leading to CD4(+)
, 2008
Host-derived interleukin-18 differentially impacts regulatory
, 2007
A novel technique for the enrichment of primary ovarian cancer cells
, 2007
CD101 surface expression discrimites potency among murine FoxP3(+) regulatory T cells
, 2007
In vivo dymics of regulatory T-cell trafficking
, 2007
Early CD30 sigling is critical for adoptively transferred CD4(+)CD25(+) regulatory T cells
, 2007
Role of turally arising regulatory T cells in hematopoietic cell transplantation
, 2006
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease.
, 2006
Innovation - In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease
, 2006
Protective conditioning for acute graft-versus-host disease - Reply
, 2005
Silencing human NKG2D, DAP10
, 2005
Ex vivo expanded dendritic cells home to T
, 2005
Protective conditioning for acute graft-versus-host disease
, 2005
In vivo alyses of early events in acute graft-versus
, 2005
Role of NKG2D sigling in the cytotoxicity of activated and expanded CD8(+) T cells
, 2004
CD4(+)CD25(+) regulatory T cells preserve graft-versus
, 2003
Advancing animal models of neoplasia through in vivo bioluminescence imaging
, 2002
Visualization of effective tumor targeting by CD8+tural killer T cells redirected with bispecific
, 2002
Studies of ex vivo activated and expanded CD8(+) NK-T cells in humans and mice
, 2002
Understanding immune cell trafficking patterns via in vivo bioluminescence imaging
, 2002
Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence
, 2002
Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kise show growth
, 2001
Expansion of cytolytic CD8
, 2001
Transplantation of bone marrow as compared with peripheral-blood cells from HLA
, 2001
CD2-mediated IL-12-dependent sigls render human gamma delta-T cells resistant to mitogen-induced
, 2000
Effect of oral glutamine supplementation during bone marrow transplantation
Total lymphoid irradiation-antithymocyte globulin conditioning
, 2014
Donor hematopoiesis in mice following total lymphoid irradiation requires host T
, 2014
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes
, 2014
Role of lymphocyte activation gene-3
, 2014
Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells.
, 2013
IL-17 Gene Ablation Does Not Impact Treg
, 2013
Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic
, 2013
A distinct evolution of the T
, 2013
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third
, 2013
Murine anti-third-party central-memory CD8
, 2013
A diagnostic window for the treatment of acute graft-versus
, 2013
Cancer Vaccines and T Cell Therapy
, 2013
Mapping immune processes in intact tissues at cellular resolution.
, 2012
Mapping immune processes in intact tissues at cellular resolution
, 2012
Prophylactic rituximab after allogeneic transplantation decreases B
, 2012
Rapid development of exhaustion
, 2012
Co-transplantation of pure blood stem cells with antigen
, 2012
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative
, 2012
Tandem chemo-mobilization followed by high
, 2012
Long-term outcomes after transplantation of HLA
, 2012
Cytomegalovirus Viral Load
, 2012
Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy
, 2012
Adoptive Immunotherapy with Cytokine
, 2011
Role of regulatory T cell populations in controlling graft vs host disease
, 2011
Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased
, 2011
Autologous versus Reduced
, 2011
Low doses of natural killer T cells provide protection from acute graft-versus
, 2011
CD8(+)CD44(hi) but not CD4(+)CD44(hi) memory T cells mediate potent graft antilymphoma activity
, 2011
Short-Term Immunosuppression Promotes Engraftment of Embryonic and Induced Pluripotent Stem Cells
, 2011
Long-term outcomes in patients with high
, 2011
Natural and Expanded CD4(+) CD25(+) Regulatory T Cells in Bone Marrow Transplantation
, 2011
CXCL12 Mediates Immunosuppression
, 2010
Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells
, 2010
Phase I/II Trial of GN-BVC
, 2010
CD11B+CD11C+DENDRITIC CELLS INTERACT WITH ALLOREACTIVE T CELLS IN THE INTESTINAL MUCOSA IN ACUTE
, 2010
DIFFERENCES IN ALLOREACTIVE T CELL MIGRATION IN MHC MATCHED VERSUS MHC MISMATCHED HCT
, 2010
NK cells mediate reduction of GVHD by inhibiting activated
, 2010
Simultaneous blockade of several endothelial lig
, 2010
Biology and clinical effects of natural killer cells in allogeneic transplantation
, 2010
Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged
, 2010
Immunoglobulin G Fc Receptor Fc gamma RIIIa 158 V
, 2010
Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells
, 2009
Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation
, 2009
TLI and ATG conditioning with low risk of graft-versus
, 2009
Natural Killer Cells in Allogeneic Transplantation: Effect on Engraftment, Graft- versus-Tumor
, 2009
Regulation of different inflammatory diseases by impacting the mevalonate pathway
, 2009
Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation
, 2009
Follicular lymphoma B cells induce the conversion of conventional CD4
, 2009
Impact of mammalian target of rapamycin inhibition on lymphoid homing
, 2008
In vivo trafficking
, 2008
Plasmacytoid dendritic cells take up opsonized antigen leading to CD4(+)
, 2008
Long-term remission of Philadelphia chromosome
, 2008
Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma
, 2008
Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs
, 2008
Interleukin-2 receptor downstream events in regulatory T cells
, 2008
The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation
, 2008
Differential impact of mammalian target of rapamycin inhibition on CD4(+)CD25(+)Foxp3(+)
, 2008
Preemptive HMG-CoA reductase inhibition provides graft
, 2007
Host-derived interleukin-18 differentially impacts regulatory
, 2007
A novel technique for the enrichment of primary ovarian cancer cells
, 2007
CD101 surface expression discriminates potency among murine FoxP3(+) regulatory T cells
, 2007
In vivo dynamics of regulatory T-cell trafficking
, 2007
Early CD30 signaling is critical for adoptively transferred CD4(+)CD25(+) regulatory T cells
, 2007
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid
, 2007
Promise and challenges of human regulatory T cells in the clinic
, 2007
Role of naturally arising regulatory T cells in hematopoietic cell transplantation
, 2006
High-dose carmustine, etoposide
, 2006
Inhibition of CD4(+)CD25(+) regulatory T-cell function by calcineurin
, 2006
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease.
, 2006
Innovation - In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease
, 2006
Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic
, 2006
Synergistic antitumor effects of immune cell-viral biotherapy
, 2006
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine
, 2006
The apoptotic and proliferative fate of cytokine
, 2006
Total lymphoid irradiation and transplantation tolerance
, 2006
Protective conditioning for acute graft-versus-host disease - Reply
, 2005
Silencing human NKG2D, DAP10
, 2005
Ex vivo expanded dendritic cells home to T
, 2005
Protective conditioning for acute graft-versus-host disease
, 2005
In vivo analyses of early events in acute graft-versus
, 2005
Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection
, 2005
Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine
, 2005
A phase I trial of autologous cytokine
, 2005
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem
, 2005
Hematopoietic stem and progenitor cells
, 2005
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8(+) T cells
, 2004
Evaluation of effector cell fate and function by in vivo bioluminescence imaging
, 2003
CD4(+)CD25(+) regulatory T cells preserve graft-versus
, 2003
Revealing lymphoma growth
, 2003
Advancing animal models of neoplasia through in vivo bioluminescence imaging
, 2002
Visualization of effective tumor targeting by CD8+natural killer T cells
, 2002
Studies of ex vivo activated and expanded CD8(+) NK-T cells in humans and mice
, 2002
Understanding immune cell trafficking patterns via in vivo bioluminescence imaging
, 2002
Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence
, 2002
Bioluminescence imaging of lymphocyte trafficking in vivo
, 2001
Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth
, 2001
Rapid engraftment after allogeneic transplantation of density
, 2001
Expansion of cytolytic CD8
, 2001
Survivin expression correlates with apoptosis resistance after lymphocyte activation
, 2001
CD58/LFA-3 and IL-12 provided by activated monocytes
, 2001
Transplantation of bone marrow as compared with peripheral-blood cells from HLA
, 2001
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first
, 2001
High-dose therapy and autologous hematopoietic
, 2001
Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients
, 2001
CD31 mismatching affects marrow transplantation outcome
, 2001
Efficacy and toxicity of a CCNU-containing high
, 2001
Engineering hematopoietic grafts
, 2001
CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced
, 2000
Resistance of ex vivo expanded CD3(+)CD56(+) T cells to Fas-mediated apoptosis
, 2000
Effect of oral glutamine supplementation during bone marrow transplantation
What is Dr. Negrin's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Negrin's National Provider Identifier (NPI) number is 1285791756.
What common questions do patients ask about Dr. Negrin?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Negrin
What is Dr. Robert Negrin's specialty?
Dr. Negrin is a Hematologist near Stanford, CA.
What does a Hematologist do?
An internist with advanced training specializing in disorders of the blood, spleen, and lymphatic system. This specialist manages conditions such as anemia, clotting disorders, sickle cell disease, hemophilia, leukemia, and lymphoma.
Is this Dr. Robert Negrin affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Negrin is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Hematologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Hematologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Robert Negrin accepting new patients in Stanford, CA?
Yes, Dr. Robert Negrin is accepting new patients at this time.
Does Dr. Robert Negrin offer online booking?
Please contact Dr. Negrin's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Robert Negrin?
Please contact Dr. Negrin's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Robert Negrin have?
Dr. Robert Negrin is certified by the American Board of Internal Medicine.
Other Hematologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients